From the Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University; Rheumatology Section, Veterans Affairs (VA) Portland Health Care System, Portland, Oregon, USA.
J. Desmarais, MD, Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University; C.Q. Chu, MD, PhD, Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, and Rheumatology Section, VA Portland Health Care System.
J Rheumatol. 2019 Jul;46(7):748-750. doi: 10.3899/jrheum.180393. Epub 2018 Nov 15.
To evaluate the efficacy and safety of anakinra in inpatient management of acute gout and pseudogout.
Hospitalized patients with acute gout (n = 77) or pseudogout (n = 11) or both (n = 3) were analyzed for response to anakinra and adverse effects.
Half of all patients had comorbidities limiting the treatment choice. Anakinra was well tolerated, and 92% of gout flares and 79% of pseudogout flares responded to treatment.
Anakinra is an effective and safe treatment for acute gout and pseudogout in hospitalized patients, particularly in those with comorbidities.
评估阿那白滞素在急性痛风和假性痛风住院患者管理中的疗效和安全性。
分析了 77 例急性痛风、11 例假性痛风或两者均有的住院患者对阿那白滞素的反应和不良反应。
一半的患者有合并症，限制了治疗选择。阿那白滞素耐受性良好，92%的痛风发作和 79%的假性痛风发作对治疗有反应。
阿那白滞素是治疗住院患者急性痛风和假性痛风的有效且安全的药物，特别是在合并症患者中。
